UConn Health tests intravenous immunotherapy medication OX40

UConn Health’s Neag Comprehensive Cancer Center is one of a few centers nationwide recruiting patients for a new clinical trial testing a novel immunotherapy’s ability to battle the most common and aggressive form of primary liver cancer called hepatocellular carcinoma (HCC).

http://today.uconn.edu/school-stories/clinical-trial-tackle-advanced-liver-cancer/